Literature DB >> 16863427

Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.

Cindy Q Xia1, Johnny J Yang, Liang-Shang Gan.   

Abstract

Breast cancer resistance protein (BCRP), also known as ABCG2, ABCP and MXR, is a member of the ATP-binding cassette transporter G family. BCRP functions as a biological barrier that extrudes xenobiotics out of cells. The broad substrate specificity and tissue distributions of BCRP in the body make this transporter one of the major efflux transporters in chemotherapy. Recent studies have demonstrated that BCRP exerts a great impact on drug absorption and disposition. This review focuses on the role of BCRP in pharmacokinetics as well as in vitro and in vivo strategies to evaluate hepatic/intestinal BCRP-mediated drug transports and drug-drug interactions. The impacts of polymorphism and gender difference of BCRP are also discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16863427     DOI: 10.1517/17425255.1.4.595

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  8 in total

Review 1.  Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades.

Authors:  Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

2.  Multidrug resistance protein 1 (MRP1) in rabbit conjunctival epithelial cells: its effect on drug efflux and its regulation by adenoviral infection.

Authors:  Johnny J Yang; David K Ann; Ram Kannan; Vincent H L Lee
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.200

Review 3.  Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier.

Authors:  David S Miller
Journal:  Trends Pharmacol Sci       Date:  2010-04-24       Impact factor: 14.819

4.  The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.

Authors:  Kimberly K Adkison; Soniya S Vaidya; Daniel Y Lee; Seok Hwee Koo; Linghui Li; Amar A Mehta; Annette S Gross; Joseph W Polli; Yu Lou; Edmund J D Lee
Journal:  Br J Clin Pharmacol       Date:  2008-04-22       Impact factor: 4.335

5.  Antipsychotic drugs inhibit the function of breast cancer resistance protein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; Hong-Jie Yuan; C Lindsay Devane
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-10       Impact factor: 4.080

Review 6.  The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

Authors:  Yasmine Nivoix; Dominique Levêque; Raoul Herbrecht; Jean-Claude Koffel; Laurence Beretz; Genevieve Ubeaud-Sequier
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 7.  BCRP/ABCG2 in the placenta: expression, function and regulation.

Authors:  Qingcheng Mao
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

8.  Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.

Authors:  Floriane Montanari; Anna Cseke; Katrin Wlcek; Gerhard F Ecker
Journal:  SLAS Discov       Date:  2016-07-11       Impact factor: 3.341

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.